文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges.

作者信息

Keshwania Puja, Kaur Narinder, Chauhan Jyoti, Sharma Gajanand, Afzal Obaid, Alfawaz Altamimi Abdulmalik Saleh, Almalki Waleed H

机构信息

Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana 133207, India.

University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Studies, Panjab University, Chandigarh 160014, India.

出版信息

ACS Omega. 2023 Aug 22;8(35):31575-31599. doi: 10.1021/acsomega.3c01988. eCollection 2023 Sep 5.


DOI:10.1021/acsomega.3c01988
PMID:37692246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10483660/
Abstract

The most prevalent infection in the world is dermatophytosis, which is a major issue with high recurrence and can affect the entire body including the skin, hair, and nails. The major goal of this Review is to acquire knowledge about cutting-edge approaches for treating dermatophytosis efficiently by adding antifungals to formulations based on nanocarriers in order to overcome the shortcomings of standard treatment methods. Updates on nanosystems and research developments on animal and clinical investigations are also presented. Along with the currently licensed formulations, the investigation also emphasizes novel therapies and existing therapeutic alternatives that can be used to control dermatophytosis. The Review also summarizes recent developments on the prevalence, management approaches, and disadvantages of standard dosage types. There are a number of therapeutic strategies for the treatment of dermatophytosis that have good clinical cure rates but also drawbacks such as antifungal drug resistance and unfavorable side effects. To improve therapeutic activity and get around the drawbacks of the traditional therapy approaches for dermatophytosis, efforts have been described in recent years to combine several antifungal drugs into new carriers. These formulations have been successful in providing improved antifungal activity, longer drug retention, improved effectiveness, higher skin penetration, and sustained drug release.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/4bf87c3eeac5/ao3c01988_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/8daf67a4a256/ao3c01988_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/df655c93ee20/ao3c01988_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/edee346e59dc/ao3c01988_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/4c142a999a9e/ao3c01988_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/4bf87c3eeac5/ao3c01988_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/8daf67a4a256/ao3c01988_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/df655c93ee20/ao3c01988_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/edee346e59dc/ao3c01988_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/4c142a999a9e/ao3c01988_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10cc/10483660/4bf87c3eeac5/ao3c01988_0005.jpg

相似文献

[1]
Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges.

ACS Omega. 2023-8-22

[2]
Nanotechnological interventions in dermatophytosis: from oral to topical, a fresh perspective.

Expert Opin Drug Deliv. 2019-4-3

[3]
Naftifine: A Topical Allylamine for Superficial Dermatophytosis.

J Assoc Physicians India. 2023-5

[4]
Tuberculosis

2017-11-3

[5]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[6]
Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).

Indian Dermatol Online J. 2020-7-13

[7]
Conventional and natural compounds for the treatment of dermatophytosis.

Med Mycol. 2020-8-1

[8]
Determination of antifungal minimum inhibitory concentration and its clinical correlation among treatment failure cases of dermatophytosis.

J Family Med Prim Care. 2019-8-28

[9]
In vivo antifungal activity of dipyrithione against Trichophyton rubrum on guinea pig dermatophytosis models.

Biomed Pharmacother. 2018-9-20

[10]
Topical and systemic antifungals in dermatology practice.

Expert Rev Clin Pharmacol. 2017-2

引用本文的文献

[1]
Exploring the Diversity and Distribution of Medico-Veterinary Fungal Diseases in Africa: Harnessing a Multisectoral One Health Strategy for Cost-Effective Prevention and Preparedness.

J Fungi (Basel). 2025-7-30

[2]
subsp. : an assessment of its antifungal, antidiabetic, anti-aging, and neuroprotective potential.

Front Pharmacol. 2025-7-7

[3]
Discovery of semisynthetic derivatives of ()- and ()-usnic acids as potential antifungal agents against and .

RSC Med Chem. 2025-7-10

[4]
Foam-Based Drug Delivery Systems for Skin Disorders: A Comprehensive Review.

AAPS PharmSciTech. 2025-4-4

[5]
Development of nanospray loaded with ciclopirox for dermal fungus treatment: determination of pro-inflammatory interleukin IL-2 mRNA expression.

BMC Pharmacol Toxicol. 2025-2-14

[6]
Layer-by-Layer Biopolymer-Coated Deformable Liposomes-In Situ Gel: A Hybrid Strategy for Enhanced Ocular Delivery of Itraconazole: In Vitro and In Vivo Appraisal.

Gels. 2024-12-31

[7]
In vitro activity of nanoliposomal amphotericin B against terbinafine-resistant Trichophyton indotineae isolates.

Int Microbiol. 2024-11-30

[8]
Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced by .

Pharmaceutics. 2024-7-25

[9]
Host-Pathogen Interaction and Resistance Mechanisms in Dermatophytes.

Pathogens. 2024-8-4

[10]
Humans vs. Fungi: An Overview of Fungal Pathogens against Humans.

Pathogens. 2024-5-17

本文引用的文献

[1]
Antifungals: From Pharmacokinetics to Clinical Practice.

Antibiotics (Basel). 2023-5-9

[2]
Essential oil and nanocarrier-based formulations approaches for vaginal candidiasis.

Ther Deliv. 2023-3

[3]
Development of miconazole nitrate nanoparticles loaded in nanoemulgel to improve its antifungal activity.

Saudi Pharm J. 2023-4

[4]
Miconazole for the treatment of vulvovaginal candidiasis. , and clinical results. Review of the literature.

J Obstet Gynaecol. 2023-12

[5]
Formulation of Miconazole-Loaded Chitosan-Carbopol Vesicular Gel: Optimization to In Vitro Characterization, Irritation, and Antifungal Assessment.

Pharmaceutics. 2023-2-8

[6]
Itraconazole-loaded microemulsions: formulation, characterization, and dermal delivery using shed snakeskin as the model membrane.

Pharm Dev Technol. 2023-1

[7]
A pH-tuned chitosan-PLGA nanocarrier for fluconazole delivery reduces toxicity and improves efficacy against resistant Candida.

Int J Biol Macromol. 2023-2-1

[8]
Development and Evaluation of Topical Ethosomal Gel for Fungal Infections.

Drug Res (Stuttg). 2023-1

[9]
An Updated Account on Formulations and Strategies for the Treatment of Burn Infection - A Review.

Curr Pharm Des. 2022

[10]
A prospective clinical and trichoscopic study of tinea capitis in children during treatment.

Dermatol Ther. 2022-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索